Physician profile
Alan Gingold
NPI 1578670253
$4,098.32
in general payments reported to CMS, 2019-2025
29 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $476 · 2021: $294 · 2022: $293 · 2023: $192 · 2024: $715 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $836.58 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $800.73 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $552.48 | 2019-2025 | Entyvio |
| Genzyme Corporation | $239.36 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $153.31 | 2019-2020 | |
| Allergan, INC. | $139.20 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $130.99 | 2024-2025 | Tremfya |
| Celltrion USA INC. | $122.18 | 2025 | Zymfentra |
| Novo Nordisk INC | $117.76 | 2025 | Wegovy |
| Pfizer INC. | $96.06 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $91.80 | 2024 | Iqirvo |
| Amgen INC. | $76.77 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $62.57 | 2020-2024 | Linzess |
| Ucb, INC. | $60.93 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $54.87 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $48.17 | 2023-2024 | Rebyota |
| Ethicon US, LLC | $45.13 | 2019-2021 | |
| Daiichi Sankyo INC. | $42.88 | 2019-2020 | |
| Qol Medical, LLC | $38.78 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $35.92 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $23.97 | 2025 | Resolution 360 Clip |
| Ardelyx, INC. | $22.20 | 2023 | Ibsrela |
| Sanofi Pasteur INC. | $19.62 | 2024 | |
| Sanofi US Services INC. | $19.27 | 2025 | |
| Alfasigma USA, INC. | $14.34 | 2020 | |
| Shire North American Group INC | $13.89 | 2019 | |
| Medtronic, INC. | $13.71 | 2022 | |
| Concordia Pharmaceuticals INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.